Mersana Therapeutics, Inc. (NASDAQ:MRSN) Analysts Are More Bearish Than They Used To Be
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Analysts Are More Bearish Than They Used To Be
Today is shaping up negative for Mersana Therapeutics, Inc. (NASDAQ:MRSN) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting the analysts have soured majorly on the business.
對於Mersana Therapeutics,Inc. (NASDAQ:MRSN)的股東來說,今天的情況不太妙,分析師對今年的預測進行了大幅度的負面修正。營業收入和每股收益(每股收益)的預測都被下調,這表明分析師對業務非常失望。
Following the latest downgrade, the current consensus, from the ten analysts covering Mersana Therapeutics, is for revenues of US$26m in 2024, which would reflect a considerable 12% reduction in Mersana Therapeutics' sales over the past 12 months. Losses are presumed to reduce, shrinking 18% per share from last year to US$0.70. However, before this estimates update, the consensus had been expecting revenues of US$38m and US$0.62 per share in losses. Ergo, there's been a clear change in sentiment, with the analysts administering a notable cut to this year's revenue estimates, while at the same time increasing their loss per share forecasts.
在最新的降級之後,Mersana Therapeutics的10位分析師的共識是,2024年收入爲2600萬美元,這表明Mersana Therapeutics過去12個月銷售額大幅下降了12%。預計損失將減少,每股減少18%至0.70美元。然而,在這一估計更新之前,共識預計營業收入爲3800萬美元,每股損失爲0.62美元。因此,情緒顯然發生了明顯的改變,分析師對今年的營收預期進行了顯著的下調,同時加大了每股的損失預期。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240815/0-3433c4b91dd9fd6d35e7bbdb2f15dbb6-0-b72cd54c77ed57008823847b19c5df67.png/big)
There was no major change to the consensus price target of US$6.44, signalling that the business is performing roughly in line with expectations, despite lower earnings per share forecasts.
共識的目標股價仍爲6.44美元,這表明儘管每股收益預測較低,業務仍在符合預期。
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We would highlight that sales are expected to reverse, with a forecast 23% annualised revenue decline to the end of 2024. That is a notable change from historical growth of 16% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 23% per year. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Mersana Therapeutics is expected to lag the wider industry.
我們還可以從更大的背景下看待這些預期,比如預測與過去的業績相比如何,以及預測與行業內其他企業相比是否更爲看好。我們應該指出,預計銷售將反轉,預計年化收入下降23%至2024年底。這是一個顯著的變化,過去五年的歷史增長率達16%。與我們的數據相比,該行業其他公司的總體預期年收入增長率爲23%。因此,儘管其營業收入預計會收縮,但Mersana Therapeutics有可能落後於更廣泛的行業。
The Bottom Line
最重要的事情是分析師增加了它對下一年每股虧損的估計。令人欣慰的是,營收預測未發生重大變化,業務仍有望比整個行業增長更快。共識價格目標穩定在28.50美元,最新估計不足以對價格目標產生影響。
The most important thing to note from this downgrade is that the consensus increased its forecast losses this year, suggesting all may not be well at Mersana Therapeutics. Regrettably, they also downgraded their revenue estimates, and the latest forecasts imply the business will grow sales slower than the wider market. We're also surprised to see that the price target went unchanged. Still, deteriorating business conditions (assuming accurate forecasts!) can be a leading indicator for the stock price, so we wouldn't blame investors for being more cautious on Mersana Therapeutics after the downgrade.
這次降級最重要的一點是,共識預計今年的虧損將增加,這表明Mersana Therapeutics並非一切進展順利。遺憾的是,他們還調低了營收預測,最新預測暗示該公司的銷售增長將低於整個市場。我們也很驚訝地看到目標股價沒有變化。然而,嚴峻的業務情況(如果預測準確!)可以成爲股價的領先指標,因此我們不會因降級後對Mersana Therapeutics更爲謹慎而責怪投資者。
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Mersana Therapeutics going out to 2026, and you can see them free on our platform here.
話雖如此,在未來幾年公司收益的長期軌跡比明年更重要。在Simply Wall St,我們對Mersana Therapeutics的分析師預測進行了全面的研究,可預測至2026年,您可以在我們的平台上免費查看這些預測。
Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.
跟蹤管理層是購買還是銷售,是尋找可能達到關鍵點的有趣公司的另一種方法,我們的免費公司列表由內部支持的增長公司組成。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。